SCLC,Extensive Stage research hub

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

This study looks at adding a drug called niraparib to regular immunotherapy for people with a specific type of advanced small cell lung cancer (SCLC). It aims to see if this addition helps control the cancer better after initial treatment.